News
MNKD
3.380
+2.11%
0.070
MannKind Shareholders Reaffirm Board, Pay, and Auditor Roles
TipRanks · 2d ago
Weekly Report: what happened at MNKD last week (0511-0515)?
Weekly Report · 6d ago
MannKind EVP, General Counsel David Thomson disposes 15,420 shares worth $53,624.52
PUBT · 05/14 00:30
MannKind director Steven B. Binder disposes of 22,500 shares worth $75,927.40
PUBT · 05/14 00:30
Weekly Report: what happened at MNKD last week (0504-0508)?
Weekly Report · 05/11 10:23
MannKind Leans Into Growth Amid Earnings Volatility
TipRanks · 05/08 02:17
MannKind Is Maintained at Sector Perform by RBC Capital
Dow Jones · 05/07 17:56
MannKind Price Target Raised to $4.75/Share From $3.50 by RBC Capital
Dow Jones · 05/07 17:56
BUZZ-U.S. STOCKS ON THE MOVE-Krispy Kreme, Tesla, Axon Enterprise
Reuters · 05/07 17:50
RBC Capital Maintains Sector Perform on MannKind, Raises Price Target to $4.75
Benzinga · 05/07 17:46
MannKind targets $110M-$120M 2026 FUROSCIX revenue as it nears May 29 and July 26 PDUFA catalysts
Seeking Alpha · 05/07 17:02
MannKind: It's Complicated
Seeking Alpha · 05/07 16:50
MannKind price target lowered to $7 from $8 at Mizuho
TipRanks · 05/07 15:49
BUZZ-U.S. STOCKS ON THE MOVE-Albemarle, Howmet, Travere Therapeutics 
Reuters · 05/07 15:41
MannKind Price Target Raised to $10.00/Share From $8.00 by Wells Fargo
Dow Jones · 05/07 15:14
MannKind Is Maintained at Overweight by Wells Fargo
Dow Jones · 05/07 15:14
Wells Fargo Maintains Overweight on MannKind, Raises Price Target to $10
Benzinga · 05/07 15:04
MANNKIND CORP SHARES MARGINALLY DOWN AFTER CO SWINGS TO NET LOSS
Reuters · 05/07 13:40
MannKind Price Target Cut to $7.00/Share From $8.00 by Mizuho
Dow Jones · 05/07 12:50
MannKind Is Maintained at Outperform by Mizuho
Dow Jones · 05/07 12:50
More
Webull provides a variety of real-time MNKD stock news. You can receive the latest news about Mannkind through multiple platforms. This information may help you make smarter investment decisions.
About MNKD
MannKind Corporation is a biopharmaceutical company engaged in transforming chronic disease care through patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. Its commercial assets include Afrezza, FUROSCIX and V-Go along with Tyvaso DPI. Its commercializing Afrezza (insulin human) Inhalation Powder, an ultra-rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease product, Tyvaso DPI (treprostinil) inhalation powder, is used in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).